Logo Logo
Group by: Item Type | Date
Number of items: 3.

Journal article

Schoffski, Patrick; Kubickova, Michaela; Wozniak, Agnieszka; Blay, Jean-Yves; Strauss, Sandra J.; Stacchiotti, Silvia; Switaj, Tomasz; Bucklein, Veit; Leahy, Michael G.; Italiano, Antoine; Isambert, Nicolas; Debiec-Rychter, Maria; Sciot, Raf; Lee, Che-Jui; Speetjens, Frank M.; Nzokirantevye, Axelle; Neven, Anouk and Kasper, Bernd (2021): Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. In: European Journal of Cancer, Vol. 156: pp. 12-23

Ray-Coquard, Isabelle; Hatcher, Helen; Bompas, Emmanuelle; Casado, Antonio; Westermann, Annekke; Isambert, Nicolas; Casali, Paolo Giovanni; Pratap, Sarah; Stark, Daniel; Valverde, Claudia; Anand, Anjana; Huizing, Manon; Floquet, Anne; Lindner, Lars; Hermes, Barbara; Seddon, Beatrice; Coens, Corneel; Jones, Robin and Reed, Nick (2020): A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment (EORTC62113). In: International Journal of Gynecological Cancer, Vol. 30, No. 10: pp. 1633-1637

Schoffski, Patrick; Sufliarsky, Jozef; Gelderblom, Hans; Blay, Jean-Yves; Strauss, Sandra J.; Stacchiotti, Silvia; Rutkowski, Piotr; Lindner, Lars H.; Leahy, Michael G.; Italiano, Antoine; Isambert, Nicolas; Debiec-Rychter, Maria; Sciot, Raf; Cann, Thomas van; Marreaud, Sandrine; Nzokirantevye, Axelle; Collette, Sandra and Wozniak, Agnieszka (2018): Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. In: Lancet Respiratory Medicine, Vol. 6, No. 6: pp. 431-441

This list was generated on Sun May 19 03:07:31 2024 CEST.